VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Second primary malignancy after treatment with ruxolitinib

Francesca Palandri, PhD, MD, University Hospital, Bologna, Italy, explores the incidence of second primary malignancies after treatment with ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter